Acute Cardiotoxicity
Acute Cardiotoxicity - Related Videos
04:47
Zebrafish Cardiomyopathy Model: Drug-Induced Cardiotoxicity
0 Views •
2023
This video describes the technique of creating a zebrafish cardiomyopathy model with minimal variations among experimental groups and in the sample, we create zebrafish cardiomyopathy model using the drug doxorubicin.
11:00
Using Chicken Embryo as a Powerful Tool in Assessment of Developmental Cardiotoxicities
0 Views •
Cited by 2 •
2021
Chicken embryos, as a classical developmental model, are used in our lab to assess developmental cardiotoxicities following exposure to various environmental contaminants. Exposure methods and morphological/functional assessment methods established are described in this manuscript.
07:45
Acute Myocardial Infarction in Rats
0 Views •
Cited by 103 •
2011
The rat model of acute myocardial infarction (AMI) is useful to study the consequence of a MI on cardiac pathophysiological and physiological function.
07:10
In vivo Imaging Method to Distinguish Acute and Chronic Inflammation
0 Views •
Cited by 25 •
2013
We describe a non-invasive imaging method for distinguishing inflammatory stages. Systemic delivery of luminol reveals areas of acute inflammation dependent upon MPO activity in neutrophils. In contrast, injection of lucigenin allows for visualization of chronic inflammation dependent upon Phox activity in macrophages.
13:32
Abdominal Exam IV: Acute Abdominal Pain Assessment
0 Views •
2023
Source: Joseph Donroe, MD, Internal Medicine and Pediatrics, Yale School of Medicine, New Haven, CT Abdominal pain is a frequent presenting concern in both the emergency department and the office setting. Acute abdominal pain is defined as pain lasting less than seven days, while an acute abdomen refers to the abrupt onset of severe abdominal pain with features suggesting a surgically intervenable process. The differential diagnosis of acute abdominal pain is broad; thus, clinicians must have a...
FAQs
The injury may arise through several pathways, including direct myocardial damage, disrupted electrical conduction, coronary ischemia, abnormal calcium handling, or impaired contractility. These mechanisms can produce different clinical consequences, such as arrhythmias, reduced cardiac output, or heart failure. Distinguishing the likely pathway helps clinicians connect observed cardiac changes with the affected aspect of heart function.
Electrical conduction coordinates the timing of cardiac activity, while calcium handling contributes to contraction. Disruption in either process can impair rhythm or pumping performance, even when the primary injury is not described simply as muscle damage. Evaluating these mechanisms helps explain why an exposure may present predominantly with arrhythmias, reduced contractility, or broader circulatory instability.
Changes can develop within hours or days, so a patient’s condition may worsen over a short interval rather than evolve gradually. Rapid recognition is especially important when cardiac dysfunction threatens circulation, because clinicians may need to reassess the suspected exposure and cardiac status promptly. The time relationship between exposure and new findings can also support evaluation of treatment safety.
Assessment combines clinical symptoms with electrocardiography, cardiac biomarkers, blood pressure measurements, and cardiac imaging. Symptoms indicate how the patient is experiencing the problem, while the other tools examine electrical activity, evidence of cardiac injury, circulatory status, and structural or functional changes. Using these findings together provides a broader assessment than relying on any single measurement.
Findings can support timely treatment and inform decisions about stopping or modifying the suspected causative exposure. Electrocardiographic, biomarker, blood pressure, imaging, and symptom changes provide complementary evidence for judging the severity and progression of cardiac dysfunction. This information helps clinicians respond to emerging arrhythmias, reduced cardiac output, or heart failure while reassessing the patient’s condition.
It provides a clinically relevant framework for examining cardiovascular safety, particularly when a therapy or intervention may affect myocardial function, rhythm, circulation, or contractility. Researchers can use the same categories of evidence, including symptoms, electrocardiography, biomarkers, blood pressure, and imaging, to identify harmful cardiac changes and assess whether a treatment requires modification or closer monitoring.